Back to search results

Deep Brain Stimulation Outcomes Study for Parkinson's, Tremor, and Dystonia

This study is looking back at existing medical records to understand how Deep Brain Stimulation (DBS) has helped people with Parkinson's Disease, Essential Tremor, and Dystonia. DBS is a treatment that involves implanting a device to send electrical signals to specific areas of the brain. Researchers want to see how much symptoms improve up to five years after the DBS device is implanted. You could be included in this study if you have already received or are eligible for a DBS system. This is an observational study, meaning researchers are simply reviewing past information, not testing a new treatment. The study aims to include information from 5000 people.

Study design
This is an observational study that will review existing, de-identified patient records. It aims to include data from 5000 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The study will look at outcomes up to 5 years after the Deep Brain Stimulation implant.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT03664609

Deep Brain Stimulation (DBS) Retrospective Outcomes Study

Recruiting
Not specifiedAll AgesObservational
Boston Scientific Corporation
~5,000 participants
Updated 2026-08-04 on ClinicalTrials.gov
What's tested:Deep Brain Stimulation

At a glance

Recruiting sites
16 of 19 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Mean Change in Unified Parkinson's Disease Rating Scale (UPDRS III) at up to 5 years post implant compared to baseline
Measured over 5 yrs. post implant

Conditions

Parkinson Disease
Essential Tremor
Dystonia

Explore related trials

DystoniaEssential TremorParkinson Disease

Where it's being run

19 sites across 13 states
Germany5
Florida2
Belgium2
Arizona1
California1
Idaho1
New York1
North Carolina1

Study leadership

  • Natalie Bloom Lyons · STUDY_DIRECTOR · Boston Scientific Neuromodulation Corporation

Who to contact

Cleo Mertz
[email protected]
855-213-9890
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Must be previously treated with or eligible for implantation with a deep brain stimulation system

What this trial measures

  • Mean Change in Unified Parkinson's Disease Rating Scale (UPDRS III) at up to 5 years post implant compared to baseline5 yrs. post implant

    Improvement in disease symptoms as assessed by Unified Parkinson's Disease Rating Scale (UPDRS III) at up to 5 years post implant compared to baseline